Friday, July 20, 2018
 
 
Company News: Page (1) of 1 - 07/11/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Generalized Anxiety Disorder Market: By Therapeutics Type; By Therapies; By devices & By Geography - Forecast 2018-2023 - ResearchAndMarkets.com

(July 11, 2018)

DUBLIN--(BUSINESS WIRE)--The "Generalized Anxiety Disorder Market: By Therapeutics Type; By Therapies; By devices & By Geography - Forecast 2018-2023" report has been added to ResearchAndMarkets.com's offering.


This report identifies the generalized anxiety disorder market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to generalized anxiety disorder market.

Globally North America dominated the market for generalized anxiety disorder in 2015 with highest market share due to higher research and development activities by pharmaceutical industry in the region. North America was followed by Europe as the second largest regional market for generalized anxiety disorder due to higher patients complaining about stressful life style resulting into GAD. However, Asia-Pacific is expected to remain fastest growing regional segment during the period of study due to changing life style and increasing awareness about such diseases in the region.

This report identifies all the major companies operating in the global generalized anxiety disorder market. Some of the major companies' profiles in detail are as follows:



  • GlaxoSmithKline Pharmaceuticals Limited
  • Bristol-Myers Squibb
  • Sumitomo Dainippon Pharma
  • Noven Pharmaceuticals, Inc.
  • Actavis Pharmaceutical Company

Key Topics Covered:

1. Generalized Anxiety Disorder - Market Overview

2. Executive Summary

3. Market Landscape

4. Generalized Anxiety Disorder - Market Forces

5. Generalized Anxiety Disorder - Strategic Analysis

6. Generalized Anxiety Disorder Market, By Therapeutics Type

7. Generalized Anxiety Disorder Market, By Geography

8. Generalized Anxiety Disorder - Market Entropy

9. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)

For more information about this report visit https://www.researchandmarkets.com/research/7j6pb3/generalized?w=4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Anxiety Drugs


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott
  • Trauma Fixation Global Market to Register Steady Expansion During 2018-2025
  • Global Surgical Apparel Market Will Reach USD 2,966.58 million by 2024: Zion Market Research

    Cancer
  • Mesothelioma is a Deadly Cancer and itís Completely Preventable
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  • Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally - QYResearch.com
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines